December 24, 2025 01:41 am (IST)
Follow us:
Aurobindo Pharma receives USFDA approval for pain reliever tablets
Hyderabad, May 17 (IBNS) Aurobindo Pharma Limited, manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg, and 8 mg.
Hydromorphone Hydrochloride Tablets is used to relieve moderate to severe pain in patients where the use of an opioid is appropriate, the company release said.
The company said that the approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Dilaudid (hydromorphone hydrochloride) Tablets, 2 mg, 4 mg, and 8 mg of Purdue Pharma L.P.
Quoting IMS, the company said that the approved product has an estimated market size of US$ 50 million for the twelve months ending March 2016.
The company also said this is the 12th ANDA to be approved out of Aurolife formulation facility in New Jersey, US for manufacturing non-antibiotic products and controlled substances, .
Aurobindo now has a total of 263 ANDA approvals (225 Final approvals, including 12 from Aurolife Pharma LLC and 38 tentative approvals) from USFDA.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Sensex slips over 100 points at open — here’s what experts say next
Tue, Dec 23 2025
DBS Bank India extends ₹670 crore sustainability-linked trade facility to Indorama India
Mon, Dec 22 2025